User: Guest  Login
Title:

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

Document type:
Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Article
Author(s):
Müller, MC; Gattermann, N; Lahaye, T; Deininger, MW; Berndt, A; Fruehauf, S; Neubauer, A; Fischer, T; Hossfeld, DK; Schneller, F; Krause, SW; Nerl, C; Sayer, HG; Ottmann, OG; Waller, C; Aulitzky, W; Le Coutre, P; Freund, M; Merx, K; Paschka, P; König, H; Kreil, S; Berger, U; Gschaidmeier, H; Hehlmann, R; Hochhaus, A
Abstract:
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive imatinib (n=69) or interferon (IFN)/Ara-C (n=70). The response was sequentially monitored by cytogenetics from bone marrow metaphases (n=803) and qualitative and quantitative RT-PCR from peripheral blood samples (n=1117). Complete cytogenetic response (CCR) was achieved in 60 (imatinib, 87%) vs 10 patients (IFN/Ara-C, 14%) after a...     »
Journal title abbreviation:
Leukemia
Year:
2003
Journal volume:
17
Journal issue:
12
Pages contribution:
2392-400
Language:
eng
Fulltext / DOI:
doi:10.1038/sj.leu.2403157
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/14523462
Print-ISSN:
0887-6924
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX